WO2023287938A1 - Formes à l'état solide d'amcenestrant - Google Patents

Formes à l'état solide d'amcenestrant Download PDF

Info

Publication number
WO2023287938A1
WO2023287938A1 PCT/US2022/037052 US2022037052W WO2023287938A1 WO 2023287938 A1 WO2023287938 A1 WO 2023287938A1 US 2022037052 W US2022037052 W US 2022037052W WO 2023287938 A1 WO2023287938 A1 WO 2023287938A1
Authority
WO
WIPO (PCT)
Prior art keywords
amcenestrant
theta
degrees
crystalline
adipic acid
Prior art date
Application number
PCT/US2022/037052
Other languages
English (en)
Inventor
Lorena KORDIĆ
Sanja MATEČIĆ MUŠANIĆ
Tea BARBARO
Original Assignee
Teva Pharmaceuticals International Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International Gmbh, Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceuticals International Gmbh
Publication of WO2023287938A1 publication Critical patent/WO2023287938A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des formes à l'état solide d'Amcenestrant, dans des modes de réalisation, des polymorphes cristallins d'Amcenestrant, des procédés de préparation de ceux-ci, et des compositions pharmaceutiques de ceux-ci.
PCT/US2022/037052 2021-07-15 2022-07-14 Formes à l'état solide d'amcenestrant WO2023287938A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163221981P 2021-07-15 2021-07-15
US63/221,981 2021-07-15
US202163295021P 2021-12-30 2021-12-30
US63/295,021 2021-12-30
US202263317996P 2022-03-09 2022-03-09
US63/317,996 2022-03-09

Publications (1)

Publication Number Publication Date
WO2023287938A1 true WO2023287938A1 (fr) 2023-01-19

Family

ID=82839256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/037052 WO2023287938A1 (fr) 2021-07-15 2022-07-14 Formes à l'état solide d'amcenestrant

Country Status (1)

Country Link
WO (1) WO2023287938A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714221B1 (en) 2016-02-15 2017-07-25 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
WO2021116074A1 (fr) 2019-12-09 2021-06-17 Sanofi Forme cristalline d'un dérivé d'acide 7h-benzo[7]annulène-2-carboxylique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714221B1 (en) 2016-02-15 2017-07-25 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
WO2017140669A1 (fr) 2016-02-15 2017-08-24 Sanofi Dérivés de 6,7-dihydro-5h-benzo[7]annulène utilisés en tant que modulateurs de récepteurs des oestrogènes
WO2021116074A1 (fr) 2019-12-09 2021-06-17 Sanofi Forme cristalline d'un dérivé d'acide 7h-benzo[7]annulène-2-carboxylique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems"

Similar Documents

Publication Publication Date Title
WO2020232325A1 (fr) Formes solides de tafamidis et sels associés
WO2020102302A1 (fr) Formes solides de daprodustat et leurs procédés de préparation
US20210292479A1 (en) Solid state forms of sugammadex sodium
US20220315607A1 (en) Solid state forms of risdiplam and process for preparation thereof
EP4352056A1 (fr) Formes à l'état solide de lanifibranor et leur procédé de préparation
WO2023064519A1 (fr) Formes à l'état solide d'élacestrant et leurs processus de préparation
US20230167090A1 (en) Solid state forms of aprocitentan and process for preparation thereof
WO2022015557A1 (fr) Formes à l'état solide de sels de rucaparib
EP4118084A1 (fr) Formes à l'état solide d'avapritinib et leur procédé de préparation
WO2021154987A1 (fr) Formes à l'état solide de mitapivat et leur procédé de préparation
EP3947386A1 (fr) Formes à l'état solide d'acalabrutinib
EP4073058A1 (fr) Forme à l'état solide du lemborexant
EP3990113A1 (fr) Formes à l'état solide de rolupéridone et sels associés
WO2023287938A1 (fr) Formes à l'état solide d'amcenestrant
US20230278990A1 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
EP4347564A1 (fr) Forme à l'état solide de centanafadine hcl et son procédé de préparation
WO2024069574A1 (fr) Formes à l'état solide de denifanstat
WO2021216628A1 (fr) Formes solides de trifarotène et leur procédé de préparation
WO2024100599A1 (fr) Formes à l'état solide de chlorhydrate de zavégépant et leur procédé de préparation
WO2020154581A1 (fr) Formes à l'état solide d'un co-cristal de fédovapagon-acide salicylique
WO2023199258A1 (fr) Formes à l'état solide de mavacamten et leur procédé de préparation
WO2022182699A1 (fr) Formes à l'état solide de tideglusib et leur procédé de préparation
EP4229047A1 (fr) Formes à l'état solide de pralsetinib et leur procédé de préparation
EP4351734A1 (fr) Formes à l'état solide d'abexinostat et leur procédé de préparation
EP4271678A1 (fr) Formes solides de capivasertib et leur procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22751569

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE